ELAN
Income statement / Annual
Last year (2023), Elanco Animal Health Incorporated's total revenue was $4.42 B,
a decrease of 0.02% from the previous year.
In 2023, Elanco Animal Health Incorporated's net income was -$1.23 B.
See Elanco Animal Health Incorporated’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$4.42 B
|
$4.42 B
|
$4.77 B
|
$3.27 B
|
$3.07 B
|
$3.07 B
|
$2.89 B
|
$2.91 B
|
$2.91 B
|
| Cost of Revenue |
$1.93 B |
$1.91 B |
$2.13 B |
$1.67 B |
$1.47 B |
$1.57 B |
$1.49 B |
$1.41 B |
$1.53 B |
| Gross Profit |
$2.49 B |
$2.51 B |
$2.63 B |
$1.61 B |
$1.60 B |
$1.49 B |
$1.40 B |
$1.50 B |
$1.38 B |
| Gross Profit Ratio |
0.56 |
0.57 |
0.55 |
0.49 |
0.52 |
0.49 |
0.48 |
0.52 |
0.47 |
| Research and Development
Expenses |
$327.00 M
|
$321.00 M
|
$369.00 M
|
$327.00 M
|
$270.10 M
|
$246.60 M
|
$251.70 M
|
$265.80 M
|
$291.00 M
|
| General & Administrative
Expenses |
$1.08 B
|
$1.07 B
|
$1.16 B
|
$0.00
|
$0.00
|
$735.20 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$207.00 M
|
$201.00 M
|
$248.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$1.29 B
|
$1.27 B
|
$1.40 B
|
$996.60 M
|
$760.20 M
|
$735.20 M
|
$779.80 M
|
$784.80 M
|
$916.00 M
|
| Other Expenses |
-$75.00 M |
$528.00 M |
$556.00 M |
$359.90 M |
$200.40 M |
-$41.30 M |
$100,000.00 |
$2.80 M |
-$1.60 M |
| Operating Expenses |
$2.16 B |
$2.12 B |
$2.33 B |
$1.68 B |
$1.23 B |
$1.18 B |
$1.25 B |
$1.22 B |
$1.37 B |
| Cost And Expenses |
$4.09 B |
$4.03 B |
$4.46 B |
$3.35 B |
$2.70 B |
$2.75 B |
$2.75 B |
$2.63 B |
$2.90 B |
| Interest Income |
$0.00 |
$241.00 M |
$236.00 M |
$150.00 M |
$79.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$277.00 M |
$241.00 M |
$236.00 M |
$149.80 M |
$78.90 M |
$29.60 M |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$694.00 M
|
$682.00 M
|
$716.00 M
|
$516.90 M
|
$314.50 M
|
$296.00 M
|
$318.40 M
|
$254.40 M
|
$236.90 M
|
| EBITDA |
$945.00 M
|
$886.00 M
|
$853.00 M
|
$461.40 M
|
$543.00 M
|
$640.00 M
|
$835.90 M
|
$540.40 M
|
$505.60 M
|
| EBITDA Ratio |
0.21 |
0.2 |
0.18 |
0.14 |
0.18 |
0.21 |
0.29 |
0.19 |
0.17 |
| Operating Income Ratio
|
0.07
|
0.08
|
0.06
|
0.03
|
0.11
|
0.1
|
0.05
|
0.1
|
0
|
| Total Other
Income/Expenses Net |
-$1.24 B
|
-$424.00 M
|
-$864.00 M
|
-$773.50 M
|
-$264.40 M
|
-$170.10 M
|
-$375.00 M
|
-$305.60 M
|
-$264.90 M
|
| Income Before Tax |
-$1.20 B |
-$66.00 M |
-$567.00 M |
-$672.00 M |
$78.20 M |
$114.10 M |
-$232.60 M |
-$22.40 M |
-$259.50 M |
| Income Before Tax Ratio
|
-0.27
|
-0.01
|
-0.12
|
-0.21
|
0.03
|
0.04
|
-0.08
|
-0.01
|
-0.09
|
| Income Tax Expense |
$36.00 M |
$8.00 M |
-$95.00 M |
-$111.90 M |
$10.30 M |
$27.60 M |
$78.10 M |
$25.50 M |
-$48.70 M |
| Net Income |
-$1.23 B |
-$74.00 M |
-$472.00 M |
-$560.10 M |
$67.90 M |
$86.50 M |
-$310.70 M |
-$47.90 M |
-$210.80 M |
| Net Income Ratio |
-0.28 |
-0.02 |
-0.1 |
-0.17 |
0.02 |
0.03 |
-0.11 |
-0.02 |
-0.07 |
| EPS |
-2.5 |
-0.15 |
-0.97 |
-1.27 |
0.18 |
0.28 |
-0.87 |
-0.13 |
-0.59 |
| EPS Diluted |
-2.5 |
-0.15 |
-0.97 |
-1.27 |
0.18 |
0.28 |
-0.87 |
-0.13 |
-0.59 |
| Weighted Average Shares
Out |
$492.30 M
|
$488.30 M
|
$487.20 M
|
$441.40 M
|
$369.00 M
|
$313.70 M
|
$356.20 M
|
$356.20 M
|
$356.20 M
|
| Weighted Average Shares
Out Diluted |
$492.30 M
|
$488.30 M
|
$487.20 M
|
$441.40 M
|
$370.30 M
|
$313.70 M
|
$356.20 M
|
$356.20 M
|
$356.20 M
|
| Link |
|
|
|
|
|
|
|
|
|
